World's Best Scientists 2026 revealed!
Christoph Thomssen

Christoph Thomssen

D-Index & Metrics

Medicine

D-Index
79
Citations
32079
World Ranking
17377
National Ranking
909

Overview

Christoph Thomssen is affiliated with the University of Göttingen in Germany and has an extensive publication record in the fields of medicine, particularly focusing on oncology and cancer research. Their work spans over 273 publications in medicine and 128 in biochemistry, genetics, and molecular biology. Within these disciplines, key subfields include oncology, cancer research, pulmonary and respiratory medicine, pathology and forensic medicine, and molecular biology.

The main research topics covered by their publications focus on advanced breast cancer therapies, breast cancer treatment studies, HER2/EGFR in cancer research, cancer treatment and pharmacology, breast lesions and carcinomas, cancer immunotherapy and biomarkers, and cancer genomics and diagnostics.

They have contributed several notable papers, including:

  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5), 2020, Annals of Oncology
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up, 2021, Journal of Clinical Oncology
  • 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4), 2021, UNC Libraries
  • 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7), 2024, The Breast
  • St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer, 2021, Breast Care

The scientist frequently collaborates with several coauthors, including Volkmar Müller, Peter A. Fasching, Nadia Harbeck, Diana Lüftner, and Tanja Fehm.

Recurring publication venues where their work often appears include:

  • Geburtshilfe und Frauenheilkunde
  • Breast Care
  • Senologie - Zeitschrift für Mammadiagnostik und -therapie
  • Cancer Research
  • Annals of Oncology

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

    F. Cardoso;A. Costa;L. Norton;E. Senkus

  • Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

    Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

    Michael Untch;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

    F. Janicke;A. Prechtl;C. Thomssen;N. Harbeck

  • Clinical impact of the plasminogen activation system in tumor invasion and metastasis : Prognostic relevance and target for therapy

    M Schmitt;N Harbeck;C Thomssen;O Wilhelm

  • 1st International consensus guidelines for advanced breast cancer (ABC 1)

    F. Cardoso;A. Costa;L. Norton;D. Cameron

  • Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study

    Frédéric Amant;Gunter von Minckwitz;Sileny N. Han;Marijke Bontenbal

  • Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

    Jens Huober;Gunter von Minckwitz;Carsten Denkert;Hans Tesch

  • Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

    Valentina Guarneri;David Miles;Nicholas Robert;Véronique Diéras

  • uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.

    Michael J Duffy;Patricia M McGowan;Nadia Harbeck;Christoph Thomssen

  • St. Gallen 2011: Summary of the Consensus Discussion

    Michael Gnant;Nadia Harbeck;Christoph Thomssen

  • Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study

    Gunter von Minckwitz;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

    J. Huober;J. Huober;P.A. Fasching;P.A. Fasching;M. Barsoum;L. Petruzelka

  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

    Martine Piccart;Marion Procter;Debora Fumagalli;Evandro de Azambuja

  • Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study

    Volker Moebus;Christian Jackisch;Hans-Joachim Lueck;Andreas du Bois

  • Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients

    Sibylle Loibl;André Schmidt;Oreste Gentilini;Bella Kaufman

  • HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer

    Gottfried E. Konecny;Christoph Thomssen;Hans Joachim Lück;Michael Untch

Frequent Co-Authors

Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Volkmar Müller
Volkmar Müller Universität Hamburg
Peter A. Fasching
Peter A. Fasching University of Erlangen-Nuremberg
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf
Gunter von Minckwitz
Gunter von Minckwitz University of Ulm
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Matthias W. Beckmann
Matthias W. Beckmann University of Erlangen-Nuremberg
Jens Huober
Jens Huober Kantonsspital St. Gallen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to a range of related online degrees and healthcare career pathways. Many students choose to expand their career options through programs that offer flexibility and targeted knowledge.

For those interested in healthcare leadership, an accelerated healthcare administration degree allows you to gain vital management skills quickly and efficiently. Similarly, registered nurses may opt for an rn to np bridge program to advance from nursing to nurse practitioner status, often through convenient online classes.

The field of health and wellness is also growing. If you are passionate about nutrition and preventive care, a nutritionist online degree can provide thorough training while fitting into your schedule. For graduate-level advancement, a cahme accredited online mha programs list offers guidance to recognized degrees that can boost your credentials in healthcare administration.

Exploring these related pathways can broaden your expertise and increase your career opportunities in the dynamic world of health and medicine.

Best Scientists Citing Christoph Thomssen

Trending Scientists

Recently Published Articles